Tumor Treating Fields were approved for treating mesothelioma, and while they are effective, researchers want to make them more effective for the cancer. A researcher at the Humanitas University in Milan is studying different drug combinations to use with Tumor Treating Fields. The goal is to find a drug that[…]
Overall Survival
CAR-T Cell Therapy and Keytruda is Showing Real Promise
Researchers at the Memorial Sloan Kettering Cancer Center are experimenting with a combination of CAR-T cell therapy and Keytruda, a PD-1 blocker for the treatment of pleural mesothelioma. This is the first time that these two therapies have been combined. The results were recently published in Cancer Discovery. Mesothelioma is[…]
A New Predictive Model Could Help Doctors Choose the Best Surgery for Mesothelioma Patients
Doctors could soon pick the best surgery for pleural mesothelioma patients because of a new predictive model created by Harvard researchers. There are different types of mesothelioma surgery: one involves removing a lung while the other leaves the lungs. The best surgery for each individual patient depends on the person’s[…]
Adjuvant Radiotherapy Does Not Improve Survival in Pleural Mesothelioma Patients
Adjuvant radiotherapy might not be the best treatment for mesothelioma sufferers because researchers at Duke and Stanford found that this therapy does not help patients live longer. The researchers analyzed a database of pleural mesothelioma patients at Duke and a national registry of patients. The research looked at the outcomes[…]
Doctors Should Use Pleurectomy Decortication Surgery Over Extrapleural Pneumonectomy Surgery
A study looking at many patients with pleural mesothelioma found that there is not enough of a survival advantage to support the use of extrapleural pneumonectomy surgery (EPP). The study was done at the MD Anderson Cancer Center at the University of Texas. EPP is the most aggressive surgery for[…]
Mesothelioma Patients with High Levels of the PD-L1 Protein Have Shorter Survival
Unfortunately for mesothelioma patients with high levels of the PD-L1 protein, they have a worse overall survival compared to patients who have lower levels. A European study looking at 200 patients wanted to see if PD-L1 and PD-1, popular targets for immunotherapy drugs, impact survival independently without immunotherapy drugs present.[…]
The Two Major Mesothelioma Surgeries Have Similar Death Rates
Japanese researchers have found that the main two types of surgery for mesothelioma have similar risks of death. The surgeries either remove the diseased lung lining and one of the lungs or just the lining. Doctors do not agree what surgery is best for mesothelioma patients, but both surgeries have[…]
A Combination of Tremelimumab and Durvalumab Can Extend Mesothelioma Survival
An Italian study has found that the combination of two immunotherapy drugs can create a long-term survival in mesothelioma patients. The two drugs, tremelimumab and durvalumab, were just given orphan drug status to treat liver cancer in the last year. The best results in the mesothelioma study were seen in[…]
A Phase III Clinical Trial is Looking at the Combination of Durvalumab and Chemotherapy to Treat Mesothelioma
A new clinical trial involving durvalumab should be closely monitored by the Food and Drug Administration. The phase III clinical trial is being performed in Baltimore, Cleveland, and Ann Arbor as well as places in New Zealand and Australia. The randomized trial is known as DREAM3R. It wants to figure[…]
Women with Pleural Mesothelioma Live Longer Compared to Men
Mesothelioma is not found in as many women as men, but studies show that women can survive longer than men. Researchers at the International Mesothelioma Program at Brigham and Women’s Hospital in Boston found that a gene can help predict the prognosis and treatment outcome for women patients with mesothelioma.[…]
